International Journal of Sciences: Basic and Applied Research
Abstract
Cirobacter freundii are currently standing as a newly emerged human pathogen causing several infection types .It may take an outbreak pattern of nosocomial infectious disease. Thus, a prototype candidate Citrobacter freundii human uro-pathogen were aimed to be laboratory developed in two versions .The first was heat killed intact[CFKV] and the second was stealth live cell wall defective[CFSLV] vaccines. Both versions were found to be; safe ,immunogenic and effective on lapin immune and challenge models. The immune efficacy was up to 80% for CF SLV and 60% for the CFKV vaccines. CFKV and CFSLV vaccines were with no mortality but with mild short lasting morbidity. The criteria of the laboratory developed C. fruendii vaccines were matching that of typhoid vaccine Ty21a.The stealth FCSLV of freundii vaccine has shown shared antigenicity with CFKV vaccine version. Such shared antigenicity was found to be of bilateral nature both in quantitative and qualitative terms. CFKV and CFSLV vaccines induced humoral antibody responses which may be of Th2 dependent B cell responses. T cell responses are far from being operable in the immune efficacy of these vaccines, since C .fruendii are neither obligate nor facultative intracellular parasites . Vaccine lapin cross challenge models are waiting to be explored in a future work